Published in Eur J Clin Microbiol Infect Dis on October 01, 1997
In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany. Antimicrob Agents Chemother (1998) 1.67
In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae. Antimicrob Agents Chemother (1998) 1.63
In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother (1999) 1.47
Ketolide treatment of Haemophilus influenzae experimental pneumonia. Antimicrob Agents Chemother (1999) 1.06
Efficacies of ABT-773, a new ketolide, against experimental bacterial infections. Antimicrob Agents Chemother (2001) 0.97
Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother (1996) 8.65
Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol (1987) 7.31
Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother (1991) 7.18
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother (1996) 5.68
In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother (1994) 3.59
Novel mechanism of macrolide resistance in Streptococcus pneumoniae. Diagn Microbiol Infect Dis (1996) 3.29
In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. Antimicrob Agents Chemother (1997) 2.65
Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA. J Antimicrob Chemother (1997) 1.25
Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study. J Clin Microbiol (1981) 8.49
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol (2000) 6.33
Evaluation of the Repliscan system for identification of Enterobacteriaceae. J Clin Microbiol (1978) 5.07
Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome (1997) 4.15
In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother (1996) 3.82
Statistical criteria for selecting quality control limits for broth microdilution susceptibility tests with 39 different antimicrobial agents. Collaborative Antimicrobial Susceptibility Testing Group. Diagn Microbiol Infect Dis (1990) 3.71
A type VII myosin encoded by the mouse deafness gene shaker-1. Nature (1995) 3.71
Helpers: effects of experimental removal on reproductive success. Science (1982) 3.70
A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nat Genet (2000) 3.63
In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother (1994) 3.59
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat (2011) 3.40
Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline. J Clin Microbiol (1989) 2.96
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol (2008) 2.95
Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin. Antimicrob Agents Chemother (1980) 2.92
Mutations in the myosin VIIA gene cause non-syndromic recessive deafness. Nat Genet (1997) 2.88
Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J Clin Microbiol (1996) 2.70
Isolation and characterization of Suv39h2, a second histone H3 methyltransferase gene that displays testis-specific expression. Mol Cell Biol (2000) 2.56
Sequence interpretation. Functional annotation of mouse genome sequences. Science (2001) 2.54
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother (1985) 2.48
Myosin VIIa participates in opsin transport through the photoreceptor cilium. J Neurosci (1999) 2.44
Autosomal dominant non-syndromic deafness caused by a mutation in the myosin VIIA gene. Nat Genet (1997) 2.40
Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob Agents Chemother (2002) 2.33
Shaker-1 mutations reveal roles for myosin VIIA in both development and function of cochlear hair cells. Development (1998) 2.23
Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin. Antimicrob Agents Chemother (1980) 2.20
In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother (2001) 2.14
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother (1991) 2.11
Organization and evolutionary progress of a dispersed repetitive family of sequences in widely separated rodent genomes. J Mol Biol (1981) 2.10
Identification and antimicrobial susceptibility of 250 Bacteriodes fragilis subspecies tested by broth microdilution methods. Antimicrob Agents Chemother (1976) 2.09
Cefuroxime, an in vitro Comparison with Six Other Cephalosporins. Proc R Soc Med (1977) 2.06
Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolates. Antimicrob Agents Chemother (1977) 2.04
A radiation hybrid map of mouse genes. Nat Genet (2001) 2.03
Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing. Antimicrob Agents Chemother (1980) 2.03
Piperacillin (T-1220), a new semisynthetic penicillin: in vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole and cefoxitin. J Antibiot (Tokyo) (1977) 2.01
BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins. J Antibiot (Tokyo) (1977) 2.00
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol (2009) 1.99
Cloning of a novel member of the low-density lipoprotein receptor family. Gene (1998) 1.97
Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965). J Clin Microbiol (1986) 1.93
Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn Microbiol Infect Dis (2000) 1.82
BL-S786, a new parenteral cephalosporin. I. A collaborative in vitro susceptibility comparison to cephalothin against 5,762 clinical bacterial isolates. J Antibiot (Tokyo) (1977) 1.81
Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin. J Antimicrob Chemother (1997) 1.79
Cefixime disk susceptibility test criteria. J Clin Microbiol (1986) 1.79
Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid. Diagn Microbiol Infect Dis (1987) 1.75
In vitro activity and disk susceptibility of Timentin: current status. Am J Med (1985) 1.70
Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob Agents Chemother (1998) 1.67
In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits. Antimicrob Agents Chemother (1983) 1.66
Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing. Antimicrob Agents Chemother (1982) 1.64
In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae. Antimicrob Agents Chemother (1998) 1.63
Comparison of in vitro antimicrobial activity of cefamandole and cefazolin with cephalothin against over 8,000 clinical bacterial isolates. Antimicrob Agents Chemother (1976) 1.61
Rosamicin: in vitro activity comparison with erythromycin and other antibiotics against clinical isolates from the genito-urinary tract and Neisseria meningitidis. J Antibiot (Tokyo) (1979) 1.61
In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits. J Antimicrob Chemother (1996) 1.59
Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria. Antimicrob Agents Chemother (1981) 1.55
Microdissection of and microcloning from the short arm of human chromosome 2. Mol Cell Biol (1986) 1.55
In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrob Agents Chemother (1995) 1.54
In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates. Antimicrob Agents Chemother (1984) 1.52
Reassessment of the "class" concept of disk susceptibility testing. Cephalothin disks versus minimal inhibitory concentrations with eleven cephalosporins. Am J Clin Pathol (1978) 1.51
Multicenter in vitro evaluation of SM-7338, a new carbapenem. Antimicrob Agents Chemother (1989) 1.50
Comparison of identification systems for Staphylococcus epidermidis and other coagulase-negative Staphylococcus species. Diagn Microbiol Infect Dis (1994) 1.49
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria. Diagn Microbiol Infect Dis (1986) 1.49
In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother (2001) 1.45
DNA topoisomerase I is essential in Drosophila melanogaster. Proc Natl Acad Sci U S A (1993) 1.44
Survival differences between black and white women with breast cancer. J Surg Oncol (1994) 1.44
Cefaclor and cefatrizine, new investigational orally administered cephalosporins. In-vitro collaborative evaluation against clinical bacterial isolates and comparison with related antimicrobics. Am J Clin Pathol (1979) 1.43
Ticarcillin, carbenicillin and BL-P1908. In vitro comparison of three anti-pseudomonal semisynthetic penicillins. J Antibiot (Tokyo) (1977) 1.43
In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests. J Antimicrob Chemother (1999) 1.43
Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates. Clin Ther (1980) 1.43
A mutation (2314delG) in the Usher syndrome type IIA gene: high prevalence and phenotypic variation. Am J Hum Genet (1999) 1.42
Prosthetic valve endocarditis: superiority of surgical valve replacement versus medical therapy only. Ann Thorac Surg (1994) 1.40
Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by disk diffusion, dilution, and anaerobic methods. J Clin Microbiol (1986) 1.40
Ticarcillin and ticarcillin-clavulanic acid susceptibility tests: error rates for disk tests with consecutively isolated members of the family Enterobacteriaceae. Antimicrob Agents Chemother (1992) 1.37
Mutations in the myosin VIIA gene cause a wide phenotypic spectrum, including atypical Usher syndrome. Am J Hum Genet (1998) 1.36
Myosin VIIA is required for aminoglycoside accumulation in cochlear hair cells. J Neurosci (1997) 1.36
Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates. Antimicrob Agents Chemother (1979) 1.34
High-performance liquid-chromatographic assay of aminoglycoside antibiotics in serum. Clin Chem (1978) 1.34
Ramoplanin susceptibility testing criteria. J Clin Microbiol (1993) 1.34
Analysis of the Pax-3 gene in the mouse mutant splotch. Genomics (1993) 1.34
Proposed disk diffusion susceptibility criteria for ofloxacin. J Clin Microbiol (1985) 1.32
Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother (1993) 1.32
Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia (2000) 1.32
Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin. J Antimicrob Chemother (1993) 1.32
Haemophilus test medium versus Mueller-Hinton broth with lysed horse blood for antimicrobial susceptibility testing of four bacterial species. Eur J Clin Microbiol Infect Dis (1993) 1.30
Evaluation of in vitro antibacterial activity of enoxacin: comparison with other orally absorbed antimicrobial agents, proposed disk diffusion test interpretive criteria, and quality control limits. Diagn Microbiol Infect Dis (1985) 1.30
Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories. J Clin Microbiol (1984) 1.30
Ceftizoxime and cefoxitin susceptibility testing against anaerobic bacteria: comparison of results from three NCCLS methods and quality control recommendations for the reference agar dilution procedure. Diagn Microbiol Infect Dis (1987) 1.29
Genetics of deafness. Curr Opin Neurobiol (1996) 1.28
The mouse slalom mutant demonstrates a role for Jagged1 in neuroepithelial patterning in the organ of Corti. Hum Mol Genet (2001) 1.28
The kyphoscoliosis (ky) mouse is deficient in hypertrophic responses and is caused by a mutation in a novel muscle-specific protein. Hum Mol Genet (2001) 1.27
The murine polycomb-group genes Ezh1 and Ezh2 map close to Hox gene clusters on mouse chromosomes 11 and 6. Mamm Genome (1999) 1.26
Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA. J Antimicrob Chemother (1997) 1.25
Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res (1997) 1.24
Effects of shaker-1 mutations on myosin-VIIa protein and mRNA expression. Cell Motil Cytoskeleton (1997) 1.24
In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother (2006) 1.24
Construction of a mouse yeast artificial chromosome library in a recombination-deficient strain of yeast. Nat Genet (1992) 1.23
Beta-adrenergic blocking activity of Yersinia pestis murine toxin. Infect Immun (1977) 1.22